Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 3, 1999, Pages 672-677

  Lacy, Melinda K ^a   Lu, Wen ^b   Xu, Xiaowei ^b   Tessier, Pamela R ^b   Nicolau, David P ^b   Quintiliani, Richard ^b   Nightingale, Charles H ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COMPARATIVE STUDY; COMPARTMENT MODEL; DRUG ELIMINATION; DRUG HALF LIFE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

EID: 0032978288     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.3.672     Document Type: Article

References (34)

1. Bartlett, J. G., and L. M. Mundy. 1995. Community-acquired pneumonia. N. Engl. J. Med. 333:1618-1624.
2. Bayer Corporation. 1997. Cipro package insert. Bayer Corporation. West Haven, Conn.
3. Cooper, B., and M. Lawlor. 1989. Pneumococcal hacteremia during ciprofloxacin therapy for pneumococcal pneumonia. Am. J. Med. 87:475. (Letter.)
4. Craig, W. A., and S. C. Ebert. 1991. Killing and regrowth of bacteria in vitro: a review. Scand. J. Infect. Dis. Suppl. 74:63-70.
5. Davies, B. I., F. P. V. Maesen, and C. Baur. 1986. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur. J. Clin. Microbiol. 5:226-231.
6. Doern, G. V., A. Brueggemann, H. P. Holley, Jr., and A. M. Rauch. 1996. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40:1208-1213.
7. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
8. Dudley, M. N. 1991. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J. Med. 91(Suppl. 6A): 45S-50S.
9. File, T. M., Jr., J. Segreti, L. Dunbar, R. Player, R. Kohler, R. R. Williams, C. Kojak, and A. Rubin. 1997. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 41:1965-1972.
10. Fine, M. J., M. A. Smith, C. A. Carson, S. S. Mutha, S. S. Sankey, L. A. Weissfeld, and W. N. Kapoor. 1996. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 275:134-141.
11. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Gross, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
12. Frieden, T. R., and R. J. Mangi. 1990. Inappropriate use of oral ciprofloxacin. JAMA 264:1438-1440.
13. Garrison, M. W., K. Vance-Bryan, T. A. Larson, J. P. Toscano, and J. C. Rolschafer. 1990. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 34:1925-1931.
14. Goldstein, F. W., J. F. Acar, and The Alexander Project Collaborative Group. 1996. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 Western Europe and USA collaborative surveillance study. J. Antimicrob. Chemother. 38(Suppl. A): 71-84.
15. Gwaltney, J. M., Jr. 1996. Acute community-acquired sinusitis. Clin. Infect. Dis. 23:1209-1223.
16. Hampel, B., H. Lode, G. Bruckner, and P. Koeppe. 1988. Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxicillin in human volunteers. Drugs 35(Suppl. 7):29-33.
17. Hansman, D., and M. M. Bullen. 1967. A resistant pneumococcus. Lancet i:264-265.
18. Kimbrough, R. C., III, W. B. Gerecht, F. C. Husted, and J. E. Wolfe. 1991. The failure of ciprofloxacin to prevent the progression of Streptococcus pneumoniae infections to meningitis. Mo. Med. 88:635-637.
19. Lafredo, S. C., B. D. Foleno, and K. P. Fu. 1993. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro. Chemotherapy (Basel) 39:36-39.
20. Lee, B. L., A. M. Padula, R. C. Kimbrough, S. R. Jones, R. E. Chaisson, J. Mills, and M. A. Sande. 1991. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N. Engl. J. Med. 325:520-521. (Letter.)
21. Marangos, M. N., A. T. Skoutelis, C. H. Nightingale, Z. Zhu, A. G. Psyrogiannis, D. P. Nicolau, H. P. Bassaris, and R. Quintiliani. 1995. Absorption of ciprofloxacin in patients with diabetic gastroparesis. Antimicrob. Agents Chemother. 39:2161-2163.
22. Meyers, B. R., P. Wilkinson, M. H. Mendelson, S. Walsh, C. Bournazos, and S. Z. Hirschman. 1991. Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers. Antimicrob. Agents Chemother. 35:2098-2101.
23. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Approved standard. NCCLS document M7-A4. 17(2):10-13. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Ortho Pharmaceutical Corporation. 1996. Levaquin package insert. Ortho Pharmaceutical Corporation, Raritan, N.J.
25. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, et al. 1998. Pharmacodynamics of levofloxacin, a new paradigm for early clinical trials. JAMA 279:125-129.
26. Raddatz, J. K., L. B. Hovde, and J. C. Rotschafer. 1996. An in vitro pharmacodynamic (PD) evaluation of trovafloxacin (T) against four strains of penicillin (P) resistant Streptococcus pneumoniae (SP), abstr. A61, p. 12. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
27. Rho, J. P., A. Jones, M. Woo, S. Castle, K. Smith, R. E. Bawdon, et al. 1989. Single-dose pharmacokinetics of intravenous ampicillin plus sulbactam in healthy elderly and young adult subjects. J. Antimicrob. Chemother. 24:573-580.
28. Righter, J. 1990. Pneumococcal meningitis during intravenous ciprofloxacin therapy. Am. J. Med. 88:548. (Letter.)
29. Ripa, S., L. Ferrante, and M. Prenna. 1990. Pharmacokinetics of sulbactam/ ampicillin in humans after intravenous and intramuscular injection. Chemotherapy (Basel) 36:185-192.
30. Schuchat, A., K. Robinson. J. D. Wenger, L. H. Harrison, M. Farley, A. L. Reingold, et al. 1997. Bacterial meningitis in the United States in 1995. N. Engl. J. Med. 337:970-976.
31. Simberkoff, M. S. 1994. Drug-resistant pneumococcal infections in the United States. JAMA 271:1875-1876. (Editorial.)
32. Thornsberry, C., P. Ogilvie, J. Kahn, and Y. Mauriz. 1997. Surveillance of antimicrobial resistance in S. pneumoniae (Sp). H. influenzae (Hi), and M. catarrhalis (Mc) in the U.S. during the 1996-97 respiratory season. Clin. Infect. Dis. 25:364. (Abstract 52.)
33. Thys, J. P. 1988. Quinolones in the treatment of bronchopulmonary infections. Rev. Infect. Dis. 10(Suppl. 1):S212-S217.
34. Zeller, V., C. Janoir, M.-D. Kitzis, L. Gutmann, and N. J. Moreau. 1997. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1973-1978.